Immunohistochemical analysis of chromogranin A and p53 expressions in ulcerative colitis–associated neoplasia: neuroendocrine differentiation as an early event in the colitis-neoplasia sequence

• Published in: Human pathology Vol. 44; no. 11; pp. 2393 - 2399
• Main Authors: Shigaki, Kotaro, Mitomi, Hiroyuki, Fujimori, Takahiro, Ichikawa, Kazuhito, Tomita, Shigeki, Imura, Johji, Fujii, Shigehiko, Itabashi, Michihiro, Kameoka, Shingo, Sahara, Rikisaburo, Takenoshita, Seiichi
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2013; Elsevier Limited
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - metabolism; Biopsy; Carcinoma; Cell Differentiation; Chromogranin A; Chromogranin A - metabolism; Colitis, Ulcerative - metabolism; Colitis, Ulcerative - pathology; Colitis, Ulcerative - surgery; Colonic Neoplasms - metabolism; Colonic Neoplasms - pathology; Diagnosis, Differential; Dysplasia; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Inflammatory bowel disease; Japan; Male; Middle Aged; Mortality; Mutation; Neoplasms - metabolism; Neoplasms - pathology; Neoplasms - surgery; Neuroendocrine Cells - pathology; Neuroendocrine differentiation; p53; Pathology; Predictive Value of Tests; Sensitivity and Specificity; Tumor Suppressor Protein p53 - metabolism; Ulcerative colitis; Japan; Dysplasia; Carcinoma; Chromogranin A; Neuroendocrine differentiation; Ulcerative colitis; p53
• ISSN: 0046-8177; 1532-8392; 1532-8392
• DOI: 10.1016/j.humpath.2013.06.008

Pancellular dysplasia involving neuroendocrine cells has been shown to be comparatively rare but crucially implicated in the development of neuroendocrine tumors in ulcerative colitis (UC). We attempted to clarify the prevalence of chromogranin A expression as a marker of neuroendocrine differentiation in UC-associated neoplasia by immunohistochemical analyses of 26 lesions of low-grade dysplasia (LGD), 32 high-grade dysplasias (HGDs) and 27 invasive cancers (INVs), along with p53 expression. We additionally assessed the utility of these proteins for differential diagnosis between LGD and HGD. Chromogranin A was considered positive when immunoreactive cells were more than 5% of neoplastic lesions, and the positivity tended to be higher in HGDs (57.7%) or INVs (46.7%) than LGDs (32.0%). Focal or diffuse nuclear staining for p53 was defined as positive. The positive rate for p53 was also higher in HGDs (59.4%; P = 0.037) or INVs (59.3%) than LGDs (30.8%). A similar trend was found in co-positivity for both proteins (HGDs, 30.7%/INVs, 26.7% versus LGDs, 12.0%). No positivity for both proteins was identified in the non-neoplastic mucosa. The combination of the two proteins improved the sensitivity (66.7%), specificity (80.0%), positive predictive value (72.7%) and negative predictive value (75.0%) for HGD as compared to p53 alone (sensitivity, 57.7%; specificity 68.0%; positive predictive value, 65.2%; negative predictive value, 60.7%). In conclusion, we show here that neuroendocrine differentiation is relatively common and represents an early event in the UC-neoplasia pathway in which p53 and chromogranin A are coordinately up-regulated. Immunohistochemical assessment of their expression might provide a useful adjunct tool for grading dysplasia in UC.